Wanbury Share Price Today

Wanbury subsidiary launches berrysoft baby range in India

Wanbury Skin Health launched berrysoft baby range in multiple Indian states. Four products live: Bathing Bar, Body Wash, Foam Shampoo, Syndet Handwash. Three more products in pipeline including Diaper Rash Cream. GST registered in 5 states; CFA licenses secured in 4 cities. Strategy leverages existing paediatrician network from cold/cough products.

Wanbury shareholders approve FY26 financials, director re-appointments

Wanbury shareholders approved FY26 financial statements and director re-appointments at the 38th AGM held on September 24, 2026. Voting results show unanimous promoter support for all resolutions, including the special resolution for Mohan Kumar Rayana's re-appointment. Public institutional investors opposed the re-appointment of Mohan Kumar Rayana by 50.92%, contrasting with 99.33% support from public non-institutions. Ms. Kala Agarwal submitted the scrutinizer report confirming all four resolutions passed with requisite majority.

Wanbury sets book closure from Sep 18 to 24 for 38th AGM

Register of Members closed from Sep 18 to Sep 24, 2026. 38th AGM scheduled for Sep 24, 2026 via VC/OAVM. Filing issued on Aug 31, 2026 under Companies Act 2013. Electronic notice sent to members as on Aug 21, 2026.

Wanbury secures EDQM approval for Rivaroxaban API, USFDA DMF clearances

Wanbury Limited announced the receipt of EDQM approval for Rivaroxaban API and USFDA DMF clearances for Paroxetine HCl and Metformin HCl. The EDQM approval allows the company to serve EU markets and other regions accepting CEPs. The USFDA clearances support ongoing Anda reviews for multiple customers, enhancing the firm's regulatory standing in key therapeutic areas including anticoagulants, antidepressants, and diabetes care.

Wanbury Q1 Results: Net Profit Falls 76% YoY to ₹3.2 Crore on Cost Pressures

Wanbury reported a sharp 76% YoY decline in Q1 net profit to ₹3.2 crore, driven by surging input costs and logistics disruptions, even as revenue grew 1.5% to ₹165 crore. EBITDA contracted to ₹16.2 crore with margins narrowing to 9.81% from 14.98% YoY. The company also completed a ₹205 crore debt refinancing, cutting borrowing costs to sub-10% per annum, and secured multiple regulatory approvals across Australia, Korea, and the US.

Wanbury receives no DMF deficiency letter from USFDA for Metformin ANDAs

Wanbury Limited confirmed regulatory compliance with the USFDA for its Metformin HCl API across multiple ANDAs, receiving no deficiency letters. Concurrently, the firm is expanding its API portfolio by filing a new DMF to target business opportunities in South Korea.